Aman Opneja, MBBS

Aman Opneja practices at Duke University Hospital in Durham, North Carolina, part of Duke University.

Aman Opneja's NPI, 1629419494, was assigned on July 9, 2013. Aman Opneja holds Alaska license 139733.

Aman Opneja's primary practice is Duke University Hospital, at 2301 Erwin Rd, Durham, NC 27705 in Durham County. The practice phone is (919) 684-8111.

Aman Opneja's primary practice is Duke University Hospital in Durham, North Carolina, part of Duke University. The medical group on file is Duke Health Integrated Practice. Dmand AI also links Aman Opneja to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Aman Opneja practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Aman Opneja's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Aman Opneja is licensed in Alaska.

CMS data shows 336 Medicare services from Aman Opneja across 5 procedure codes in 2024, for 77 Medicare patients. Medicare paid $29,367 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 77 Medicare patients who saw Aman Opneja in 2024. The largest group is 65 to 74, with 42 patients. 75% of them have high blood pressure, and 70% have high cholesterol. Their average risk score is 2.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Aman Opneja's median patient age at 72, with 47% women.

In 2024, Aman Opneja wrote 445 Medicare Part D claims for 70 patients. 87% of them were for generic drugs. CMS names the drug for 300 of them, across 13 drugs with 11 or more claims each, at $22,994 in total drug cost. In 2023, CMS named 183 claims across 7 drugs.

Aman Opneja accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Aman Opneja as offering telehealth.

CMS Open Payments shows 58 general payments to Aman Opneja from 22 drug and device companies from 2016 to 2024. Speaker and faculty fees make up the largest share, 46% of the total. Pfizer Inc. paid the most, $8,212. It also lists 7 research payments totaling $1,450 in 2023.